For instance, in the valsartan in heart failure trial, both NT-proBNP and BNP concentrations predicted all-cause mortality (hazard ratios [HRs] 2.07 and 1.87, respectively), mortality and morbidity (HRs 2.20 and 2.05, respectively), and hospitalization for HF (HRs 2.66 and 2.48, respectively) [37]. This evidence concerns the gene NPPB and heart failure.